Thrombo-inflammation response to Tocilizumab in COVID-19.
Mansour Gergi,Mary Cushman,Benjamin Littenberg,Ralph C. Budd +3 more
- Vol. 4, Iss: 8, pp 1262-1268
TLDR
Observations have suggested that severe acute respiratory syndrome coronavirus 2 can provoke a hyperimmune response in some cases that could lead to secondary organ damage.Abstract:
Background: Coronavirus disease-19 (COVID-19) spans a wide spectrum of illness. Severe cases of COVID-19 can manifest inflammation in organs other than the lung, in tissues not known to support viral replication, and also in a hypercoagulable state. These observations have suggested that SARS-CoV-2 can provoke a hyperimmune response in some cases that could lead to secondary organ damage. Methods: With evidence of elevated levels of interleuking-6 (IL-6) in patients with severe COVID-19, we conducted a small pilot off-label compassionate care study of the IL-6 receptor inhibitor tocilizumab patients with severe COVID-19. Results: Following a single infusion of tocilizumab in patients with severe manifested rapid declines in C-reactive protein (CRP), D-Dimer, and gradual rises in lymphocyte and platelet counts. Conclusions: These findings suggest both pathophysiological mechanisms as well as clinical benefit that might be seen with IL-6 inhibition in severe COVID-19.read more
Citations
More filters
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Journal ArticleDOI
Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19.
Panagiotis Theofilis,Marios Sagris,Alexios S. Antonopoulos,Evangelos Oikonomou,Costas Tsioufis,Dimitris Tousoulis +5 more
TL;DR: In this paper, the impact of inflammation on platelet activation in atherosclerosis has been investigated and the role of pro-inflammatory cytokines has also been highlighted, such as platelet factor-4, myeloperoxidase, and platelet-derived mediators.
References
More filters
Journal ArticleDOI
Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression.
TL;DR: Using rabbit models of S. aureus infective endocarditis, pneumonia and sepsis, and molecular genetics techniques, the mechanisms of SAg and endotoxin synergism in the pathogenesis of TSS are elucidated, and cellular and molecular mechanisms underlying SAg-mediated immune dysfunction are examined.
Journal ArticleDOI
The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature.
TL;DR: Focused history, physical examination, and laboratory testing are important for the diagnosis and management of TSS, a potentially deadly disease requiring prompt recognition and treatment.
Journal ArticleDOI
1918 H1N1 Influenza Virus Replicates and Induces Proinflammatory Cytokine Responses in Extrarespiratory Tissues of Ferrets
Emmie de Wit,Jurre Y. Siegers,Jacqueline Cronin,Sarah Weatherman,Judith M. A. van den Brand,Lonneke M. Leijten,Peter van Run,Lineke Begeman,Henk-Jan van den Ham,Arno C. Andeweg,Trenton Bushmaker,Dana P. Scott,Greg Saturday,Vincent J. Munster,Heinz Feldmann,Debby van Riel +15 more
TL;DR: The data support the suggested link between 1918 H1N1 infection and central nervous system disease and suggest that cytokine responses in tissues outside the respiratory tract likely contributed to the severity of infection.
Journal ArticleDOI
Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.
Pilar Brito-Zerón,Xavier Bosch,Marta Perez-de-Lis,Roberto Pérez-Alvarez,Guadalupe Fraile,Hoda Gheitasi,Soledad Retamozo,Albert Bové,Ester Monclús,Ona Escoda,Asunción Moreno,Armando López-Guillermo,Munther A. Khamashta,Manuel Ramos-Casals +13 more
TL;DR: In patients receiving biological therapies who develop HLH, searching for a concomitant infectious process is mandatory, and specific surveillance for EBV/CMV infections (in patients with IBD and for bacteria), including mycobacteria (in elderly patients receiving anti-TNF therapy), is recommended.